for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akers Biosciences Inc

AKER.OQ

Latest Trade

0.42USD

Change

0.01(+2.49%)

Volume

13,085

Today's Range

0.40

 - 

0.43

52 Week Range

0.39

 - 

3.92

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.41
Open
0.40
Volume
13,085
3M AVG Volume
3.38
Today's High
0.43
Today's Low
0.40
52 Week High
3.92
52 Week Low
0.39
Shares Out (MIL)
12.51
Market Cap (MIL)
5.13
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2019 Akers Biosciences Inc Earnings Release

Latest Developments

More

Akers Biosciences Reports Q2 2019 Earnings

Akers Biosciences Reports Q1 Operating Loss Of $0.9 Mln

Akers Biosciences - Anticipated That Trading In Common Stock On Aim Will Cease, Delisting Will Take Effect, From 7.00 A.M. (Gmt) On March 29

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Akers Biosciences Inc

Akers Biosciences, Inc. develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company's product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives. The Company's primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company's main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.

Industry

Biotechnology & Drugs

Contact Info

201 Grove Rd

+1.856.8488698

http://www.akersbio.com

Executive Leadership

Howard R. Yeaton

Chief Executive Officer, Interim Chief Financial Officer

Christopher C Schreiber

Independent Director

Joshua N. Silverman

Independent Director

Bill Joe White

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
2.68
Price To Book (MRQ)
1.19
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-114.28
Return on Equity (TTM)
-92.94

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up